MOASC Programs - Save the Dates - All Times are Pacific

Please go to this link for details on the following outstanding programs MOASC brings to you.

Sign up now to receive the MOASC Job Flash™! Please activate your new job alert.

Thank you for using our service at https://moasc.careerwebsite.com

MOASC Clinical Trial Database is on the MOASC website at www.moasc.org

We NEED YOUR HELP regarding unfairness of DIR fees. MOASC is continuing to work Community Oncology Alliance (COA) and Congressional representatives and senators to fix this issue, but we still need YOUR help! We have heard from some practices that they are losing money from one specific plan through ESI/Prime, where DIR fees are being charged. If this is happening to your practice, please email moasc@moasc.org so that we can help you. 

The company that was awarded the state’s Medi-Cal prescription drug contract was taken over by insurer Centene, which has been accused of overbilling nine other state Medicaid programs.

Please go to this link for details on the following Noridian programs

Members, and staff, of the Medicare Payment Advisory Commission (MedPAC) considered three different options for regulating the price of Part B drugs, which are administered by physicians in their offices. 1) For new "first-in-class" drug, 2) For drugs that already have therapeutic alternatives, and 3) To address concerns about the ASP-plus-6% reimbursement formula.

CMS proposes indefinite delay of radiation oncology payment model after the federal agency proposed a new rule on April 6.

The Open Payments Frequently Asked Questions (FAQs) have been revised, and the most recent version is now available.

It would be illegal to compel clinicians to write "dispense as written" on a prescription when a biosimilar or a generic is available per the Generic Substitution Non-Interference Act, introduced in the House and Senate last Thursday.

The OIG recommended that CMS should promote biosimilars to reduce Part D spending, but utilization would have to increase for significant savings to be realized.

Physicians will soon have new guidelines on how and when to prescribe opioids for pain.

Published by the Centers for Disease Control and Prevention, The Community Guide has updated and streamlined the What Works Fact Sheet for skin cancer prevention. 

Application deadline is this Thursday, April 14, for ANCO’s Travel Awards to Fellows and Young Clinicians to support attendance at the ASCO Annual Meeting, ASH Annual Meeting, or other national oncology meeting in 2022 are now being accepted. 

ASCO is currently accepting applications for its project to improve rates of recommended vaccinations for adults with cancer. The project is part of a five-year cooperative agreement  between the Centers for Disease Control and Prevention (CDC) and the Council of Medical Specialty Societies (CMSS). ASCO will select seven participants for the project in the Spring of 2022. Eligible participants include healthcare systems, hospitals, and private practices that managed at least 10,000 active hematology and oncology patients last year, or that meet one or more high-priority criteria in treatment of underserved populations. Interested health systems must apply by April 29, 2022. Applications must include a letter of support from a senior officer of the health system.

2022 ASCO Annual Meeting, McCormick Place, Chicago June 3 – 7, 2022.

Don’t miss the new ASH Guideline Implementation Champions Webinar taking place on Monday, April 18 at 12:30 Pacific. Learn how to implement ASH clinical practice guidelines to improve patient care.

ADC Therapeutics is seeking a passionate and driven Hematology Therapeutic Specialist for their Anaheim, CA area. This position will cover Orange and Riverside County, a portion of LA County and the Palm Springs area. ADC Therapeutics is proud to be an Affirmative Action/EEO Employer. EOE Minorities/Females/Protected Veterans/Disabled.

The Medical Oncology Association of Southern California (MOASC) is a leading oncology society that advances and protects the ability of cancer patients to obtain, and the ability of the oncology physicians to provide, optimal cancer care. The material contained in the California Oncology Weekly is intended as general information for MOASC members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the California Oncology Weekly may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in California Oncology Weekly should not be used as a substitute for such advice. This publication provides a summary of regulations affecting oncology and its business practices. Reading this newsletter does not substitute for understanding regulations and verifying the validity of every claim. This information is time-sensitive and is subject to change. MOASC accepts no liability for any statements or articles herein. CPT codes are owned and trademarked by the American Medical Association. All Rights Reserved.